Related Experiment Video
Updated: Jul 4, 2025
Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus MRSA in Rat
Published on: June 4, 2012
The Purine Biosynthesis Repressor, PurR, Contributes to Vancomycin Susceptibility of Methicillin-resistant
Yan Q Xiong1,2,3, Yi Li1, Mariya I Goncheva4
1The Lundquist Institute for Biomedical Innovation, Harbor-University of California Los Angeles Medical Center, Torrance, California, USA.
Background:
Staphylococcus aureus is the most common cause of life-threatening endovascular infections, including infective endocarditis (IE). These infections, especially when caused by methicillin-resistant strains (MRSA), feature limited therapeutic options and high morbidity and mortality rates.
Methods:
Herein, we investigated the role of the purine biosynthesis repressor, PurR, in virulence factor expression and vancomycin (VAN) treatment outcomes in experimental IE due to MRSA.
Results:
The PurR-mediated repression of purine biosynthesis was confirmed by enhanced purF expression and production of an intermediate purine metabolite in purR mutant strain. In addition, enhanced expression of the transcriptional regulators, sigB and sarA, and their key downstream virulence genes (eg, fnbA, and hla) was demonstrated in the purR mutant in vitro and within infected cardiac vegetations. Furthermore, purR deficiency enhanced fnbA/fnbB transcription, translating to increased fibronectin adhesion versus the wild type and purR-complemented strains. Notably, the purR mutant was refractory to significant reduction in target tissues MRSA burden following VAN treatment in the IE model.
Conclusions:
These findings suggest that the purine biosynthetic pathway intersects the coordination of virulence factor expression and in vivo persistence during VAN treatment, and may represent an avenue for novel antimicrobial development targeting MRSA.
Insights
The purine repressor PurR influences Staphylococcus aureus virulence and vancomycin treatment failure in endocarditis. Targeting purine biosynthesis may offer new strategies against MRSA infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Molecular Biology
Background:
- Staphylococcus aureus is a leading cause of life-threatening endovascular infections like infective endocarditis (IE).
- Methicillin-resistant Staphylococcus aureus (MRSA) strains present limited treatment options and high mortality rates in IE.
- Vancomycin (VAN) is a critical antibiotic for MRSA infections, but resistance and treatment failures are significant concerns.
Purpose of the Study:
- To investigate the role of the purine biosynthesis repressor, PurR, in MRSA virulence.
- To determine the impact of PurR on vancomycin (VAN) treatment outcomes in experimental infective endocarditis (IE).
- To explore potential novel antimicrobial targets within the purine biosynthesis pathway.
Main Methods:
- Utilized a murine model of experimental IE caused by MRSA.
- Generated and characterized a purR mutant strain of MRSA.
- Assessed virulence factor expression (sigB, sarA, fnbA, hla) in vitro and in vivo.
- Quantified bacterial burden in cardiac vegetations following VAN treatment.
Main Results:
- PurR deficiency led to enhanced expression of virulence regulators (sigB, sarA) and downstream genes (fnbA, hla).
- The purR mutant exhibited increased fibronectin binding, suggesting enhanced adhesion.
- MRSA strains lacking PurR were less responsive to VAN treatment, showing reduced bacterial burden reduction in target tissues.
- PurR-mediated repression of purine biosynthesis was confirmed by purF expression and metabolite analysis.
Conclusions:
- The purine biosynthetic pathway is intertwined with the regulation of MRSA virulence factors.
- PurR plays a crucial role in MRSA's ability to persist during vancomycin treatment in IE.
- Targeting the purine biosynthesis pathway presents a promising strategy for developing new antimicrobial therapies against MRSA.
